MedTrace Logo

Comparison of Efficacy in SBRT of Large HCC With or Without TACE

NCT04512846 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-06-27

No results posted yet for this study

Summary

The study aims to compare efficacy and adverse reactions of large hepatocellular carcinoma participants (5-10cm) who receive stereotactic body radiation therapy with or without transcatheter arterial chemoembolization.The investigators will optimize the combined treatment schedule of SBRT for hepatocellular carcinoma participants by comparing overall survival rates, progression-free survival rates and local control and adverse reaction occurrence rates in the two groups.

Conditions

  • Large HCC Patients
  • Stereotactic Body Radiation Therapy
  • Transcatheter Arterial Chemoembolization

Sponsors & Collaborators

  • Beijing 302 Hospital

    lead OTHER

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2023-08-01
Completion
2026-08-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04512846 on ClinicalTrials.gov